JAMPRO
9.8.2021 20:32:12 CEST | Business Wire | Press release
The Caribbean’s leader in renewable energy, Jamaica, is making significant strides in boosting the diversification of its energy sector, as the government looks to implement the island’s ambitious Integrated Resource Plan (IRP).
The initiative has set a goal of adding around 1,600 megawatts (MW) of generation capacity over the next 20 years to expand the island’s energy resources. The aim is to facilitate reduced energy prices, and decrease vulnerability of the energy sector to external shocks such as oil prices. The IRP creates business opportunities in the form of requests for proposals (RFPs) that seek investors to fulfill the demand for more energy generation.
The IRP’s targets include 1260 MW of wind and solar, 330 MW of liquid natural gas (LNG), and 74 MW of hydro, biomass or waste energy by the year 2037. JAMPRO, Jamaica’s investment promotions agency, is tasked with securing the local and foreign investment that will drive the plan’s success, and the achievement of these targets.
The island is well on its way. Jamaica wants to have 33 per cent of electricity generation from renewables by 2030, and there are already impressive renewable energy projects on the island that are proving to be a strong foundation for the country’s energy resource plan. The 20-megawatt (MW) Content Solar Ltd. solar energy electricity generation plant owned by WRB Energy Company in Clarendon is one such example. In Westmoreland, the largest photovoltaic power plant in Jamaica, the 51 MWp (megawatts-peak) Paradise Park solar farm, is one of the island’s cheapest producers of energy.
There is also the Wigton Windfarm in Rose Hill, Manchester, which is the largest facility of its kind in the Caribbean with a 20.7 MW plant and an 18 MW extension facility. Jamaica’s energy provider, the Jamaica Public Service (JPS)’s Munro Wind Farm has a 3 MW capacity, while Blue Mountain Renewable (BMR) Jamaica Wind generates 34 MW. In St. Elizabeth, the JPS utility company operates a 7.2 MW hydro-electric plant in Maggoty.
Regarding these projects, Don Gittens, JAMPRO’s Manager of Logistics, Energy, and Infrastructure, stated “Current renewable energy projects represent approximately 14 per cent of energy generation in Jamaica, but our target is 50 per cent . There is therefore a significant opportunity because we have that gap between 14 per cent and 50 per cent that we intend to fill with additional renewable energy investments .”
Jamaica is currently seeking to procure 320 MW of wind and solar, 120 MW of LNG and 74 MW of hydro, biomass or waste energy for this year. Gittens elaborated, “That is the opportunity that exists right now for investors, so, these are very exciting times .”
Interest high in Jamaica’s energy sector
According to JAMPRO, there is serious interest in Jamaica’s energy sector. The Agency is entertaining several local and international investors who are interested in partaking in the RFP that is to come with the aforementioned energy generation opportunities.
This interest was maintained by JAMPRO through the pandemic, as the organisation chose to intensify its marketing activities. The company increased its digital outreach and direct engagements with sector leaders and business executives locally and internationally.
Diane Edwards, President of JAMPRO, said, “While there was a feeling of uncertainty, especially at the beginning of the pandemic, we knew that we had to continue to nurture our relationships and the renewable energy opportunity in Jamaica, and increase our marketing activities. COVID-19 re-emphasised the fact that sectors like logistics, energy, and agriculture must be major priorities, so the Jamaican government really used this time to identify the areas that needed even more focus as we continue Jamaica’s development.”
Sector development initiatives have continued, and JAMPRO has partnered with entities like New Energy Events and the REA - The Association for Renewable Energy & Clean Technology in the UK to continue its global promotion of the energy industry. Jamaica has also begun work on the development of an electronic vehicle charging network, confirming the country’s commitment to alternative energy sources.
“This is a very exciting time within the local and global energy sector as everything is moving towards renewable energy ,” Gittens enthused. “Once the RFPs are ready, we are confident there will be a lot of investment coming through .”
ABOUT JAMPRO
The Jamaica Promotions Corporation (JAMPRO)’s mission is to drive economic development through growth in investment and export. JAMPRO is an Agency of the Ministry of Industry, Investment, and Commerce.
For more information on JAMPRO, please visit https://dobusinessjamaica.com/ .
Follow us on:
Twitter
Facebook
Instagram
LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005015/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
